造血干细胞移植 英语是什么意思 - 英语翻译

• hematopoietic stem cell transplantation
• hematopoietic stem cell transplant

在 中文 中使用 造血干细胞移植 的示例及其翻译为 英语

岁以下患者应积极进行造血干细胞移植；.
Patients under 50 years old should actively undergo hematopoietic stem cell transplantation;

月17日将进行造血干细胞移植。
That will be followed by the stem cell transplant on January 17.

下一篇：什么是造血干细胞移植？?
Next Page: What is a Blood Stem Cell Transplant?

这是第四次慢性疾病造血干细胞移植(HSCT)出现逆转。
This is the fourth chronic disease hematopoietic stem cell transplantation(HSCT) has appeared to reverse.

治疗选择包括类固醇、化疗和造血干细胞移植(HSCT)。
Treatment options include steroids, chemotherapy and hematopoietic stem cell transplant(HSCT).

异基因造血干细胞移植：可以大大提升治疗效果，主要用于有合适提供者的年轻患者。
Allogeneic hematopoietic stem cell transplantation: can greatly improve the treatment effect and is mainly used to young patients who have suitable providers.

使用造血干细胞移植的主要障碍包括供体细胞的供应有限和缺乏有效的收集方法。
Major barriers to using hematopoietic stem cell transplantation include the limited supply of donor cells and the lack of efficient means to harvest them.

或抗原的特异性HLAHLA被识别在测试过程中，以确保固体器官或造血干细胞移植的兼容性。
Specific HLA genes or antigens are identified during HLA testing to ensure solid organ or hematopoietic stem cell transplant compatibility.

这种被称为造血干细胞移植(HSCT)一直是某些癌症的治疗方法。
The approach, called hematopoietic stem cell transplantation(HSCT), has long been part of certain cancer treatments.

该方法称为造血干细胞移植（HSCT），长期以来一直是某些癌症治疗的一部分。
Called hematopoietic stem cell transplantation(HSCT), has long been part of certain cancer treatments.

这些患者可接受最多4轮Blincyto的治疗，并且可以选择在接受治疗后任何时间接受造血干细胞移植疗法。
These patients can receive up to 4 rounds of Blincyto treatment and can choose to receive hematopoietic stem cell transplantation at any time after treatment.

由于UCART19在患者体内的持续时间有限，接受UCART19的儿科患者随后接受了造血干细胞移植疗法。
Due to the limited duration of UCART19 in patients, pediatric patients receiving UCART19 subsequently received hematopoietic stem cell transplantation.

根据国家心脏，肺和血液研究所，造血干细胞移植是镰状细胞病唯一的治疗方法。
According to the National Heart, Lung and Blood Institute, hematopoietic stem cell transplants are the only cure for sickle cell disease.

目前的治疗方案，包括预防性抗生素、抗真菌药物和造血干细胞移植都具有显著的相关风险和局限性。
Current treatment options, including prophylactic antibiotics, antifungals, and hematopoietic stem cell transplants all have significant associated risk and limitations.

年，Escolar博士的团队就发现造血干细胞移植对克拉伯病的治疗效益至少可以持续三年。
In 2005, Dr Escolar's research showed that haematopoietic stem cell transplants had at least three years of benefits.

但是，每年有将近5万人接受造血干细胞移植，他们可能潜在地受益于这种介入性治疗。
But almost 50,000 people a year receive blood-producing stem cell transplants and could potentially be helped by such an intervention.

一旦我们更好地了解造血干细胞壁龛，我们就能够让造血干细胞移植变得更加安全。
Once we understand the niche better, we can make blood stem cell transplants much safer.”.

这是第四个出现逆转的慢性疾病造血干细胞移植(HSCT)。
This is the fourth chronic disease hematopoietic stem cell transplantation(HSCT) has appeared to reverse.

目前许多影响造血干细胞移植成功率的因素都还没有得到发现。
Many of the factors affecting the success of stem cell transplantations are still unknown.

随后我们将这些造血干细胞移植回小鼠体内，SIRT7提高了造血细胞的再生能力。
We then transplanted the blood stem cells back into mice, and SIRT7 improved the blood stem cells' regenerative capacity.".

感染是造血干细胞移植（HSCT）后的主要关注点，也是导致移植相关死亡的主要原因。
Infection is a main concern after haemopoietic stem cell transplantation(HSCT) and a major cause of transplant-related mortality.

对于大部分患者来说，B-ALL可通过化疗和造血干细胞移植的方式进行治疗。
For a vast number of patients, B-ALL can be treated by chemotherapy and stem cell transplant.

总体而言，大约一半接受造血干细胞移植的患者随后会患上某种形式的移植物抗宿主病。
In general, about one half of all patients who receive a stem cell transplant go on to develop some form of graft-versus-host disease.

尽管T-ALL可通过化疗和造血干细胞移植治疗，但约75%的患者会在两年内复发[1]….
While T-ALL is treatable by chemotherapy and stem cell transplant, around 75% of patients will relapse within two years1.

接受BESPONSA治疗的患者中有48%进行了造血干细胞移植（HSCT），而接受化疗的患者这一比例只有22%。
In addition, 48% of patients randomised with BESPONSA® proceeded to hematopoietic stem cell transplantation(HSCT), compared to 22% of patients treated with chemotherapy.

并于今年3月进行了造血干细胞移植。
This cord blood stem cell transplant took place last year.

多次试验正在进行中，以不断提高疗程效益和降低骨髓和造血干细胞移植的风险。
Several trials are underway to continue to improve the effectiveness and reduce the risks of bone marrow and stem cell transplants.

到今年底，中国造血干细胞捐献者资料库共成功配型60余例，并为31名患者成功进行了造血干细胞移植手术。
The end of 2002, China hematopoietic stem cell donors database of successful matching more than 60 cases, and 31 patients with successful hematopoietic stem cell transplant.

静脉输入最低的剂量出现在MSC和造血干细胞共移植的临床实验中，为0.3x10*5/kg。
The lowest dose of intravenous injection appeared in clinical trials of MSC and hematopoietic stem cell co-transplantation, which was 0.3x10* 5/ kg.